{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:42:36Z","timestamp":1785825756197,"version":"3.56.0"},"reference-count":182,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2022-NR067412"],"award-info":[{"award-number":["RS-2022-NR067412"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS2022-NR067425"],"award-info":[{"award-number":["RS2022-NR067425"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:32:22Z","timestamp":1764117142000},"page":"289-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemical evolution of antibody\u2013drug conjugates focused on linker design and conjugation strategies in hematology"],"prefix":"10.1053","volume":"62","author":[{"given":"Seungbin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali B.","family":"Gone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3501-212X","authenticated-orcid":false,"given":"Sang J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.11.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103193","article-title":"Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: population-based estimates from GLOBOCAN 2022","volume":"83","author":"Sun","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the ``biological missile'' for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020032","article-title":"Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0008","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jconrel.2012.01.026","article-title":"Antibody-drug conjugates: basic concepts, examples and future perspectives","volume":"161","author":"Casi","year":"2012","journal-title":"J Control Release"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bjc.1983.4","article-title":"Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer","volume":"47","author":"Ford","year":"1983","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102943","article-title":"Antibody-drug conjugates-a tutorial review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"McKertish","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0013","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CCO.0000000000001065","article-title":"Update of antibody\u2013drug conjugates for hematological malignancies","volume":"36","author":"Sun","year":"2024","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020303","article-title":"CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0015","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0016","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116709","article-title":"Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads","volume":"276","author":"Xi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0023","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2025.1628789","article-title":"AI-driven innovation in antibody-drug conjugate design","volume":"5","author":"Noriega","year":"2025","journal-title":"Front Drug Discov"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.11.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0026","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0028","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody\u2013drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4161\/mabs.28965","article-title":"Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies","volume":"6","author":"Deslandes","year":"2014","journal-title":"mAbs"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0031","article-title":"Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates","author":"Gao","year":"2025","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0032","series-title":"Antibody-Drug Conjugates","first-page":"41","article-title":"Selecting an optimal antibody for antibody\u2013drug conjugate therapy: internalization and intracellular localization","author":"Harper","year":"2013"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0033","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/oncolo\/oyad246","article-title":"Predicting response to antibody drug conjugates: a focus on antigens\u2019 targetability","volume":"28","author":"Ascione","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0038","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Sel"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/antib10020020","article-title":"Clinical pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez de S\u00e1","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0041","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10677","article-title":"Antibody drug conjugates in the clinic","volume":"9","author":"Udofa","year":"2024","journal-title":"Bioeng Transl Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.004_bib0043","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0044","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0045","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/acs.jmedchem.1c01920","article-title":"Rational design and systemic appraisal of an EGFR-targeting antibody\u2013drug conjugate LR-DM1 for pancreatic cancer","volume":"65","author":"Zhu","year":"2022","journal-title":"J Med Chem"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0046","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1021\/bc050201y","article-title":"Reduction\u2212Alkylation strategies for the modification of specific monoclonal antibody disulfides","volume":"16","author":"Sun","year":"2005","journal-title":"Bioconjugate Chem"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0047","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"6, Part 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0048","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.biotechadv.2015.05.001","article-title":"Current methods for the synthesis of homogeneous antibody\u2013drug conjugates","volume":"33","author":"Sochaj","year":"2015","journal-title":"Biotechnol Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.004_bib0049","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1110\/ps.051478705","article-title":"Structural characterization of the maytansinoid\u2013monoclonal antibody immunoconjugate, huN901\u2013DM1, by mass spectrometry","volume":"14","author":"Wang","year":"2005","journal-title":"Protein Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/asia.200800427","article-title":"Chemical modification of proteins at cysteine: opportunities in chemistry and biology","volume":"4","author":"Chalker","year":"2009","journal-title":"Chem \u2013 Asian J"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0051","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cbpa.2020.04.017","article-title":"Recent advances of thiol-selective bioconjugation reactions","volume":"58","author":"Ochtrop","year":"2020","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0052","first-page":"157","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0053","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1365-2958.2011.07887.x","article-title":"Sortase enzymes in Gram-positive bacteria","volume":"82","author":"Spirig","year":"2011","journal-title":"Mol Microbiol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0054","first-page":"222","article-title":"Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers","volume":"4","author":"Peng","year":"2021","journal-title":"Antib Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0056","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejps.2019.04.015","article-title":"High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates","volume":"134","author":"Liu","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0057","article-title":"Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches","volume":"14","author":"Hussain","year":"2021","journal-title":"Pharm (Basel)"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.004_bib0058","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1073\/pnas.0807820106","article-title":"Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0059","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1515\/hsz-2018-0358","article-title":"Formylglycine-generating enzymes for site-specific bioconjugation","volume":"400","author":"Kr\u00fcger","year":"2019","journal-title":"Biol Chem"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrm.2015.11","article-title":"Protein prenylation: unique fats make their mark on biology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0061","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4939-9654-4_10","article-title":"Site-specific bioconjugation using SMARTag((R)) technology: a practical and effective chemoenzymatic approach to generate antibody-drug conjugates","volume":"2033","author":"Liu","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0062","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jacsau.2c00617","article-title":"Enzymatic bioconjugation: a perspective from the pharmaceutical industry","volume":"3","author":"Debon","year":"2023","journal-title":"JACS Au"},{"issue":"41","key":"10.1053\/j.seminhematol.2025.11.004_bib0063","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1002\/anie.201505964","article-title":"Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein\u2013drug conjugates for targeted therapy","volume":"54","author":"Lee","year":"2015","journal-title":"Angew Chem Int Ed"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0064","series-title":"Antibody-drug conjugates: Methods and protocols","first-page":"51","article-title":"Site-specific conjugation to Cys-engineered THIOMAB\u2122 antibodies","author":"Adhikari","year":"2020"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0065","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1039\/D1SC05243H","article-title":"A homogeneous high-DAR antibody\u2013drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides","volume":"13","author":"Zacharias","year":"2022","journal-title":"Chem Sci"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0066","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1078-0432.CCR-21-3261","article-title":"Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-cell non-Hodgkin lymphoma: phase 1 dose-escalation study","volume":"28","author":"Herrera","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0067","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0068","article-title":"An integrated in vivo\/in vitro protein production platform for site-specific antibody drug conjugates","volume":"10","author":"Hanson","year":"2023","journal-title":"Bioeng (Basel)"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0069","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2316872","article-title":"Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli","volume":"16","author":"Blake-Hedges","year":"2024","journal-title":"MAbs"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of site-specific antibody\u2013drug conjugates using optimized non-natural amino acids in a cell-free expression system","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjugate Chem"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0071","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/acs.oprd.6b00072","article-title":"RP-HPLC DAR characterization of site-specific antibody drug conjugates produced in a cell-free expression system","volume":"20","author":"Xu","year":"2016","journal-title":"Org Process Res Dev"},{"issue":"102","key":"10.1053\/j.seminhematol.2025.11.004_bib0072","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0073","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates","volume":"25","author":"Dennler","year":"2014","journal-title":"Bioconjugate Chem"},{"issue":"51","key":"10.1053\/j.seminhematol.2025.11.004_bib0074","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.1002\/anie.201004243","article-title":"Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase","volume":"49","author":"Jeger","year":"2010","journal-title":"Angew Chem Int Ed"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.11.004_bib0075","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1021\/acs.chemrev.1c01032","article-title":"Glycoconjugates: synthesis, functional studies, and therapeutic developments","volume":"122","author":"Shivatare","year":"2022","journal-title":"Chem Rev"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0076","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","article-title":"Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody\u2013drug conjugates","volume":"26","author":"van Geel","year":"2015","journal-title":"Bioconjugate Chem"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0077","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.apsb.2021.12.013","article-title":"One-step synthesis of site-specific antibody\u2013drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates","volume":"12","author":"Shi","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0078","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1021\/acs.bioconjchem.2c00142","article-title":"Synthesis and evaluation of three azide-modified disaccharide oxazolines as enzyme substrates for single-step Fc glycan-mediated antibody-drug conjugation","volume":"33","author":"Zhang","year":"2022","journal-title":"Bioconjugate Chem"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.11.004_bib0079","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1021\/acs.analchem.9b02192","article-title":"Comparison of analytical methods for antibody\u2013drug conjugates produced by chemical site-specific conjugation: first-generation AJICAP","volume":"91","author":"Matsuda","year":"2019","journal-title":"Anal Chem"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.11.004_bib0080","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1021\/acs.orglett.4c00878","article-title":"AJICAP-M: traceless affinity peptide mediated conjugation technology for site-selective antibody\u2013drug conjugate synthesis","volume":"26","author":"Matsuda","year":"2024","journal-title":"Org Lett"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.11.004_bib0081","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1002\/anie.201814215","article-title":"AJICAP: affinity peptide mediated regiodivergent functionalization of native antibodies","volume":"58","author":"Yamada","year":"2019","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0082","first-page":"728","article-title":"AJICAP second generation: improved chemical site-specific conjugation technology for antibody\u2013drug conjugate production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjugate Chem"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0083","first-page":"728","article-title":"AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjug Chem"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0084","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1021\/acs.orglett.5c01424","article-title":"Balancing reactivity and specificity: Fc-binding O-acyl hydroxamate reagents for site-selective antibody labeling at Lys248","volume":"27","author":"Seo","year":"2025","journal-title":"Org Lett"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0085","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1021\/acs.jmedchem.2c00084","article-title":"Site-selective antibody\u2013drug conjugation by a proximity-driven S to N acyl transfer reaction on a therapeutic antibody","volume":"65","author":"Lee","year":"2022","journal-title":"J Med Chem"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0086","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/acsmedchemlett.5c00178","article-title":"Site-selective anti-PD-L1 antibody\u2013MMAE conjugate for enhanced NSCLC therapy","volume":"16","author":"Kwon","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0087","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody\u2013drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjugate Chem"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0088","first-page":"124","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.004_bib0089","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/ijms18091860","article-title":"Development and properties of valine-alanine based antibody-drug conjugates with monomethyl auristatin E as the potent payload","volume":"18","author":"Wang","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0090","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-23-0548","article-title":"INA03: a potent transferrin-competitive antibody-drug conjugate against CD71 for safer acute leukemia treatment","volume":"23","author":"Bratti","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0091","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/bjh.19658","article-title":"Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents","volume":"205","author":"Spriano","year":"2024","journal-title":"Br J Haematol"},{"issue":"6_Supplement","key":"10.1053\/j.seminhematol.2025.11.004_bib0092","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-3139","article-title":"Abstract 3139: BL-M11D1, a novel CD33-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"84","author":"Wan","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0093","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of \u03b2-glucuronide linkers for monoclonal antibody\u2212drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjugate Chem"},{"issue":"28","key":"10.1053\/j.seminhematol.2025.11.004_bib0094","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1002\/anie.201601506","article-title":"The methylene alkoxy carbamate self-immolative unit: utilization for the targeted delivery of alcohol-containing payloads with antibody\u2013drug conjugates","volume":"55","author":"Kolakowski","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0095","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejmech.2017.08.008","article-title":"Development and evaluation of \u03b2-galactosidase-sensitive antibody-drug conjugates","volume":"142","author":"Kolodych","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0096","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173955","article-title":"A phase 1 cohort dose escalation and expansion trial to determine the safety, tolerance, maximum tolerated dose, and preliminary antineoplastic activity of IKS03 in patients with advanced B-cell non-Hodgkin lymphomas (NHL)","volume":"142","author":"Assouline","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0097","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nrm2820","article-title":"Sensors and regulators of intracellular pH","volume":"11","author":"Casey","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0098","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cancers11070957","article-title":"Novel silyl ether-based acid-cleavable antibody-MMAE conjugates with appropriate stability and efficacy","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0099","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0006-2952(96)00241-9","article-title":"Differential distribution of free and bound glutathione and cyst(e)ine in human blood","volume":"52","author":"Mills","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.11.004_bib0100","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0101","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/C6SC01831A","article-title":"Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates","volume":"8","author":"Pillow","year":"2017","journal-title":"Chem Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0102","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody\u2013drug conjugates with self-immolative disulfide linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0103","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.26136","article-title":"A phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia","volume":"96","author":"Daver","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0104","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.11.004_bib0105","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","article-title":"Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker","volume":"14","author":"Oflazoglu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0106","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0107","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0108","article-title":"A polar sulfamide spacer significantly enhances the manufacturability, stability, and therapeutic index of antibody-drug conjugates","volume":"7","author":"Verkade","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0109","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","article-title":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","volume":"375","author":"Tedeschini","year":"2024","journal-title":"J Control Release"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0110","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-23-1356","article-title":"A cell surface-binding antibody atlas nominates a MUC18-directed antibody\u2013drug conjugate for targeting melanoma","volume":"83","author":"Shi","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0111","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1535-7163.MCT-16-0038","article-title":"Development of novel quaternary ammonium linkers for antibody\u2013drug conjugates","volume":"15","author":"Burke","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0112","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejmech.2019.06.044","article-title":"Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual \u03b2-glucuronide and dipeptide triggers","volume":"179","author":"Gregson","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.004_bib0113","doi-asserted-by":"crossref","first-page":"395","DOI":"10.23736\/S0026-4806.20.07019-6","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future","volume":"111","author":"Gottardi","year":"2020","journal-title":"Minerva Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.004_bib0114","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.11.004_bib0115","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0116","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res-Dordr"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0117","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","article-title":"Phase I \/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0118","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: clinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0119","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"10168","key":"10.1053\/j.seminhematol.2025.11.004_bib0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0121","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1119510","article-title":"Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"14","author":"Dere","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0124","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0126","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0127","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.11.004_bib0128","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0129","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Devel Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.004_bib0130","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0131","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237738","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations","volume":"14","author":"Rubinstein","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.11.004_bib0133","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood.V126.23.1559.1559","article-title":"Mechanistic and pharmacodynamic studies of Adct-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"126","author":"Flynn","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0134","first-page":"1462","article-title":"The role of interleukin-2 receptor alpha in cancer","volume":"10","author":"Kuhn","year":"2005","journal-title":"FBL"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.004_bib0135","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer\u2013containing antibody\u2013drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0136","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0137","article-title":"Antibody-drug conjugates for multiple myeloma: just the beginning, or the beginning of the end?","volume":"16","author":"Ray","year":"2023","journal-title":"Pharm (Basel)"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0138","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1535-7163.MCT-12-1170","article-title":"Milatuzumab\u2013SN-38 conjugates for the treatment of CD74+ cancers","volume":"12","author":"Govindan","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.11.004_bib0139","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","author":"Sapra","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0141","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood.V128.22.4177.4177","article-title":"Denintuzumab mafodotin stimulates immune responses and synergizes with CD20 antibodies to heighten anti-tumor activity in preclinical models of non-Hodgkin lymphoma","volume":"128","author":"Van Epps","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.11.004_bib0142","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0143","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27765","article-title":"Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts","volume":"66","author":"Jones","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.11.004_bib0144","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood.V126.23.1328.1328","article-title":"A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in adults with relapsed or refractory B-lineage acute leukemia (B-ALL) and highly aggressive lymphoma","volume":"126","author":"Fathi","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","article-title":"Therapeutic advances in the targeting of ROR1 in hematological cancers","volume":"10","author":"Tigu","year":"2024","journal-title":"Cell Death Discov"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.11.004_bib0146","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient\u2013derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0147","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/01.HS9.0000847788.96420.63","article-title":"P1231: zilovertamab vedotin (MK-2140) for the treatment of non-hodgkin lymphoma: the phase 1 dose escalation and cohort expansion waveline-001 study of an anti-ROR1 antibody-drug conjugate","volume":"6","author":"Wang","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0148","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0149","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/cyto.b.22099","article-title":"Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent","volume":"102","author":"Sriram","year":"2022","journal-title":"Cytom B: Clin Cytom"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0151","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2040620716682490","article-title":"New monoclonal antibodies on the horizon in multiple myeloma","volume":"8","author":"O\u2019Donnell","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0152","series-title":"Chemical linkers in antibody\u2013drug conjugates (ADCs)","article-title":"Non-cleavable linkers: permanently linked, for better or for worse","author":"Dugal-Tessier","year":"2021"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.004_bib0153","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0154","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-23-0548","article-title":"INA03: a potent transferrin-competitive antibody\u2013drug conjugate against CD71 for safer acute leukemia treatment","volume":"23","author":"Bratti","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-185717","article-title":"Preliminary results of a phase 1, first-in-human study of INA03, an Anti-CD71 antibody-drug conjugate in patients with relapsed or refractory (R\/R) acute leukemias","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0156","first-page":"3153","article-title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.004_bib0157","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody\u2013PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0158","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/pharmaceutics11100546","article-title":"Structure and dynamics of a site-specific labeled fc fragment with altered effector functions","volume":"11","author":"Gallagher","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0159","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.004_bib0160","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.11.004_bib0161","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0162","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/acs.molpharmaceut.5b00175","article-title":"Design of coltuximab ravtansine, a CD19-targeting antibody\u2013drug conjugate (ADC) for the treatment of B-cell malignancies: structure\u2013activity relationships and preclinical evaluation","volume":"12","author":"Hong","year":"2015","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.004_bib0163","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody\u2013drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0164","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0165","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy","volume":"103","author":"Marek","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ddtec.2018.09.005","article-title":"Enzymatic strategies for (near) clinical development of antibody-drug conjugates","volume":"30","author":"van Berkel","year":"2018","journal-title":"Drug Discov Today: Technol"},{"issue":"13_Supplement","key":"10.1053\/j.seminhematol.2025.11.004_bib0167","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-5619","article-title":"Abstract 5619: Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab","volume":"78","author":"Olson","year":"2018","journal-title":"Cancer Res"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.004_bib0168","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4470.4470","article-title":"SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma","volume":"128","author":"Lewis","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.004_bib0169","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0170","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/cam4.2066","article-title":"Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker","volume":"8","author":"Shi","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.004_bib0171","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody\u2013drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0172","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1182\/blood-2021-150783","article-title":"A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"issue":"102","key":"10.1053\/j.seminhematol.2025.11.004_bib0173","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.004_bib0174","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/bloodadvances.2022008303","article-title":"Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia","volume":"7","author":"Le","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0175","article-title":"Trph-222, a novel anti-CD22 antibody drug conjugate (ADC), has signficant anti-tumor activity in NHL xenografts and is well tolerated in non-human primates","volume":"130","author":"Maclaren","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.004_bib0176","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/2472555220912955","article-title":"Advances in antibody\u2013drug conjugate design: current clinical landscape and future innovations","volume":"25","author":"Gauzy-Lazo","year":"2020","journal-title":"SLAS Discov"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.004_bib0177","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1021\/bc400042a","article-title":"Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates","volume":"24","author":"Agarwal","year":"2013","journal-title":"Bioconjugate Chem"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0178","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-142859","article-title":"A phase I pharmacokinetic (PK) and safety study of Trph-222 in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R NHL): dose-escalation results","volume":"136","author":"Hernandez-Ilizaliturri","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0179","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/01.HS9.0000847476.69621.cd","article-title":"p1152: results from a phase I pharmacokinetic (PK) and safety study of TRPH-222, a novel CD22-targeting antibody-drug conjugate, in patients with relapsed\/refractory b-cell non-Hodgkin lymphoma (R\/R NHL)","volume":"6","author":"Hernandez-Ilizaliturri","year":"2022","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2025.11.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180767","article-title":"Debio 1562M, a next generation antibody drug conjugate (ADC) targeting CD37 for AML and MDS treatment","volume":"142","author":"Ivanschitz","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.004_bib0181","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202866","article-title":"BL-M11D1, a novel CD33 antibody-drug conjugate (ADC), in patients with relapsed\/refractory acute myeloid leukemia: initial results from first-in-human phase 1 study","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.004_bib0182","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/1535-7163.MCT-23-0506","article-title":"ADCT-602, a novel PBD dimer-containing antibody-drug conjugate for treating CD22-positive hematologic malignancies","volume":"23","author":"Zammarchi","year":"2024","journal-title":"Mol Cancer Ther"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:23:34Z","timestamp":1776039814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":182,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0037196325000538"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical evolution of antibody\u2013drug conjugates focused on linker design and conjugation strategies in hematology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}